Sarepta Therapeutics Inc. in Cambridge, Mass., named Douglas Ingram its president and chief executive officer.
The biotech develops RNA-targeted therapeutics for the treatment of rare neuromuscular diseases, or those that impair the functioning of the muscles. It main drug targets Duchenne muscular dystrophy.
The company counts a market value of about $1.9 billion.
Ingram previously served as president of Irvine-based Allergan until its acquisition by Actavis PLC in 2015, which adopted Allergan PLC as its new global name. He was most recently chief executive of Chase Pharmaceuticals Corp. in Washington D.C., a biotech focused on developing treatment for neurodegenerative diseases including Alzheimer’s.
Chase was sold to Allergan in November—a little shy of a year since Ingram came onboard—for $125 million upfront.
Ingram maintains a residence in Orange County.
Ingram is replacing interim Chief Executive Edward Kaye, who announced in April that he planned to step down from Sarepta. Ingram will also serve on the company’s board of directors.